BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32694244)

  • 1. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.
    Berlot G; Tomasini A; Roman Pognuz E; Randino A; Chiella F; La Fata C; Piva M; Amato P; di Maso V; Bianco F; Gerini U; Tomietto P; Trenti T
    Nephron; 2020; 144(9):459-462. PubMed ID: 32694244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
    Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
    Intern Med; 2020 Nov; 59(22):2945-2949. PubMed ID: 32963155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
    Wang L; Peng X; Wang ZH; Cai J; Zhou FC
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5783-5787. PubMed ID: 32495916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
    Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
    Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.
    Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI
    Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.
    Cascella M; Mauro I; De Blasio E; Crispo A; Del Gaudio A; Bimonte S; Cuomo A; Ascierto PA
    Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32727107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.
    Michot JM; Albiges L; Chaput N; Saada V; Pommeret F; Griscelli F; Balleyguier C; Besse B; Marabelle A; Netzer F; Merad M; Robert C; Barlesi F; Gachot B; Stoclin A
    Ann Oncol; 2020 Jul; 31(7):961-964. PubMed ID: 32247642
    [No Abstract]   [Full Text] [Related]  

  • 9. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
    Zhao M
    Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
    Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
    Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
    [No Abstract]   [Full Text] [Related]  

  • 12. Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab.
    Mohebbi N; Abedini A; Lashgari R; Razavi F; Varahram M; Kiani A
    Adv Respir Med; 2020; 88(5):468-469. PubMed ID: 33169824
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
    Tholin B; Hauge MT; Aukrust P; Fehrle L; Tvedt TH
    J Med Case Rep; 2020 Oct; 14(1):187. PubMed ID: 33054818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of tocilizumab effect on mortality in COVID19 patients.
    Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
    Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?
    Zhang Y; Zhong Y; Pan L; Dong J
    Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).
    Lohse A; Klopfenstein T; Balblanc JC; Royer PY; Bossert M; Gendrin V; Charpentier A; Bozgan AM; Badie J; Bourgoin C; Contreras R; Mazurier I; Conrozier T; Zayet S
    Microbes Infect; 2020 Oct; 22(9):500-503. PubMed ID: 32574789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
    Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
    Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early tocilizumab treatment could improve survival among COVID-19 patients.
    Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L
    Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.